Core Viewpoint - The company, Shanghai Haoyuan Pharmaceutical Co., Ltd., is adjusting the implementation locations and delaying the timeline for its convertible bond fundraising project, specifically for the CDMO project, while ensuring that the total investment amount and production capacity remain unchanged [1][6]. Fundraising Overview - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds totaling RMB 822.35 million, with a maturity of 6 years and a face value of RMB 100 per bond [1][2]. - The funds will be stored in a dedicated account, and the company has signed a tripartite/four-party supervision agreement with the sponsor and the bank [1]. Investment Project Details - The total investment for the high-end pharmaceutical intermediates and raw materials CDMO industrialization project (Phase I) is RMB 863.51 million, with RMB 811.74 million planned to be funded from the raised capital [2][3]. Adjustments and Delays - The project site is located in the chemical park in Chengwu County, Heze City, Shandong Province, covering approximately 158 acres [3][4]. - Adjustments include relocating certain workshops and auxiliary facilities to optimize space and reduce costs, without affecting the total investment or production capacity [4][6]. - The project timeline has been extended to June 2029 due to delays in funding and the need for additional government approvals [5][6]. Impact of Adjustments - The adjustments are based on practical project implementation conditions and do not alter the investment content or total amount, ensuring no significant adverse effects on the company's operations [6][7]. - The company has followed necessary approval procedures for these adjustments, complying with relevant regulations [6][7].